Local radiotherapy in extensive-stage small-cell lung cancer sustainably boosts the clinical benefit of first-line immunotherapy: a case report

被引:0
作者
Wang, Hongming [1 ]
Wang, Nuoni [2 ]
Li, Shiyan [1 ]
Du, Yangfeng [1 ]
Wu, Tao [1 ]
Tian, Wei [1 ]
Dong, Wen [1 ]
Liu, Xiaoyang [1 ]
Zhang, Yan [1 ]
Zheng, Jiang [1 ]
Xiao, Zemin [1 ]
Wu, Zhijun [1 ]
机构
[1] Cent South Univ, Changde Hosp, Peoples Hosp Changde City 1, Xiangya Sch Med,Dept Oncol, Changde, Peoples R China
[2] Cent South Univ, Changde Hosp, Peoples Hosp Changde City 1, Xiangya Sch Med,Dept Electrocardiogram & Physiol, Changde, Peoples R China
关键词
local radiotherapy; extensive-stage small-cell lung cancer; clinical benefit; immunotherapy; case report; RADIATION-THERAPY; CHEMOTHERAPY; CARBOPLATIN; ETOPOSIDE; SURVIVAL; SCLC;
D O I
10.3389/fimmu.2024.1493740
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background Extensive-stage small-cell lung cancer (ES-SCLC) has a dismal prognosis owing to its high aggressiveness, rapid drug resistance, and early metastasis. ES-SCLC responds well to first-line chemotherapy, and chemotherapy coupled with immunotherapy can further improve overall survival. However, the long-term survival of patients remains unsatisfactory because of its high recurrence rate and the poor efficacy of second-line treatment. Although local radiotherapy is an important component of the overall treatment for ES-SCLC, its value in the age of immunotherapy remains controversial.Case description A 54-year-old male with ES-SCLC achieved a complete response (CR), as determined using enhanced computed tomography (CT) after four cycles of immunochemotherapy (serplulimab, carboplatin, and etoposide). Whole-body positron emission tomography-CT was performed during maintenance treatment with serplulimab, which showed primary lung, liver, and bone metastatic lesions with CR. However, several mediastinal lymph nodes exhibited glucose metabolism uptake, and new lesions appeared on the head. The patient underwent palliative radiotherapy of the head and consolidative thoracic radiotherapy of the chest and continued maintenance treatment with serplulimab. Subsequent magnetic resonance imaging of the head suggested good control of metastatic lesions (CR). The patient received first-line immunotherapy for approximately 20 months.Conclusions This report presents a patient with ES-SCLC who underwent local radiotherapy in addition to serplulimab as maintenance therapy. Although the programmed death-ligand 1 (PD-L1) expression level was negative and a PD-1 inhibitor instead of a PD-L1 inhibitor was used, the patient did not experience significant pneumonia during treatment, and the efficacy of the current treatment was evident. This treatment model warrants further clinical investigation.
引用
收藏
页数:7
相关论文
共 34 条
[1]   Time to abandon single-site irradiation for inducing abscopal effects [J].
Brooks, Eric D. ;
Chang, Joe Y. .
NATURE REVIEWS CLINICAL ONCOLOGY, 2019, 16 (02) :123-135
[2]  
Chen DW, 2024, J CLIN ONCOL, V42
[3]   EXTENTORCH: A randomized, phase III trial of toripalimab versus placebo, in combination with chemotherapy as a first-line therapy for patients with extensive stage small cell lung cancer (ES-SCLC) [J].
Cheng, Y. ;
Liu, Y. ;
Zhang, W. ;
Wu, L. ;
Zhou, C. ;
Wang, D. ;
Xia, B. ;
Bi, M. ;
Fu, X. ;
Li, C. ;
Chen, G. ;
Lv, D. ;
Zhao, Y. ;
Huang, J. ;
Li, M. ;
Yi, T. ;
Huang, X. ;
Yang, R. ;
Chen, Z. ;
Wang, Y. .
ANNALS OF ONCOLOGY, 2023, 34 :S1334-S1334
[4]   Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: a randomized phase 3 trial [J].
Cheng, Ying ;
Chen, Jianhua ;
Zhang, Wei ;
Xie, Chao ;
Hu, Qun ;
Zhou, Ningning ;
Huang, Chun ;
Wei, Shihong ;
Sun, Hong ;
Li, Xingya ;
Yu, Yan ;
Lai, Jinhuo ;
Yang, Huaping ;
Fang, Haohui ;
Chen, Hualin ;
Zhang, Peng ;
Gu, Kangsheng ;
Wang, Qiming ;
Shi, Jianhua ;
Yi, Tienan ;
Xu, Xingxiang ;
Ye, Xianwei ;
Wang, Daqing ;
Xie, Conghua ;
Liu, Chunling ;
Zheng, Yulong ;
Lin, Daren ;
Zhuang, Wu ;
Lu, Ping ;
Yu, Guohua ;
Li, Jinzhang ;
Gu, Yuhai ;
Li, Baolan ;
Wu, Rong ;
Jiang, Ou ;
Wang, Zaiyi ;
Wu, Guowu ;
Lin, Haifeng ;
Zhong, Diansheng ;
Xu, Yanhua ;
Shu, Yongqian ;
Wu, Di ;
Chen, Xingwu ;
Wang, Jie ;
Wang, Minghui ;
Yang, Runxiang .
NATURE MEDICINE, 2024, 30 (10) :1819-1822
[5]   Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage SCLC (RATIONALE-312): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial [J].
Cheng, Ying ;
Fan, Yun ;
Zhao, Yanqiu ;
Huang, Dingzhi ;
Li, Xingya ;
Zhang, Peng ;
Kang, Mafei ;
Yang, Nong ;
Zhong, Diansheng ;
Wang, Zhen ;
Yu, Yan ;
Zhang, Yu ;
Zhao, Jun ;
Qin, Tai ;
Chen, Chenqi ;
Leaw, Shiangjiin ;
Zheng, Wenjuan ;
Song, Yong .
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (07) :1073-1085
[6]   Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer The ASTRUM-005 Randomized Clinical Trial [J].
Cheng, Ying ;
Han, Liang ;
Wu, Lin ;
Chen, Jun ;
Sun, Hongmei ;
Wen, Guilan ;
Ji, Yinghua ;
Dvorkin, Mikhail ;
Shi, Jianhua ;
Pan, Zhijie ;
Shi, Jinsheng ;
Wang, Xicheng ;
Bai, Yuansong ;
Melkadze, Tamar ;
Pan, Yueyin ;
Min, Xuhong ;
Viguro, Maksym ;
Li, Xingya ;
Zhao, Yanqiu ;
Yang, Junquan ;
Makharadze, Tamta ;
Arkania, Ekaterine ;
Kang, Wenying ;
Wang, Qingyu ;
Zhu, Jun .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2022, 328 (12) :1223-1232
[7]  
Clinicaltrials.Gov . University of Washington, 2022, Identifier NCT05191797. Bomedemstat and maintenance immunotherapy for treatment of newly diagnosed extensive stage small cell lung cancer
[8]  
Fang WF., 2023, Immuno-Oncol Technol, V20, DOI [10.1016/j.iotech.2023.100596, DOI 10.1016/J.IOTECH.2023.100596]
[9]   DeLLphi-303: Phase Ib first-line combination study of tarlatamab, a DLL3-targeting half-life extended bispecific T-cell engager (HLE BiTE®), with carboplatin, etoposide, and PD-L1 inhibition in extensive stage small cell lung cancer (ES-SCLC) [J].
Gadgeel, S. M. ;
Al-Mondhiry, J. ;
Ahn, M-J. ;
Kim, S-W. ;
Paz-Ares, L. ;
Prenen, H. ;
Boyer, M. ;
Bustamante Alvarez, J. G. ;
Solomon, B. ;
Huang, S. ;
Minocha, M. ;
Kistler, M. ;
Sadraei, N. Hashemi .
ANNALS OF ONCOLOGY, 2022, 33 (07) :S1255-S1255
[10]   First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer [J].
Horn, L. ;
Mansfield, A. S. ;
Szczesna, A. ;
Havel, L. ;
Krzakowski, M. ;
Hochmair, M. J. ;
Huemer, F. ;
Losonczy, G. ;
Johnson, M. L. ;
Nishio, M. ;
Reck, M. ;
Mok, T. ;
Lam, S. ;
Shames, D. S. ;
Liu, J. ;
Ding, B. ;
Lopez-Chavez, A. ;
Kabbinavar, F. ;
Lin, W. ;
Sandler, A. ;
Liu, S. V. .
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (23) :2220-2229